Assertio (ASRT) Competitors $0.77 +0.05 (+6.49%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$0.76 -0.01 (-1.04%) As of 05:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. PRQR, INZY, TRDA, ACB, IMMP, NBTX, FENC, TKNO, EDIT, and SCPHShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include ProQR Therapeutics (PRQR), Inozyme Pharma (INZY), Entrada Therapeutics (TRDA), Aurora Cannabis (ACB), Prima BioMed (IMMP), Nanobiotix (NBTX), Adherex Technologies (FENC), Alpha Teknova (TKNO), Editas Medicine (EDIT), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Its Competitors ProQR Therapeutics Inozyme Pharma Entrada Therapeutics Aurora Cannabis Prima BioMed Nanobiotix Adherex Technologies Alpha Teknova Editas Medicine scPharmaceuticals ProQR Therapeutics (NASDAQ:PRQR) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Which has better valuation & earnings, PRQR or ASRT? Assertio has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Assertio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$20.46M11.16-$30.04M-$0.35-6.20Assertio$124.96M0.59-$21.58M-$0.32-2.41 Is PRQR or ASRT more profitable? Assertio has a net margin of -25.72% compared to ProQR Therapeutics' net margin of -157.04%. Assertio's return on equity of -24.87% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-157.04% -53.49% -22.07% Assertio -25.72%-24.87%-10.87% Do analysts rate PRQR or ASRT? ProQR Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 268.66%. Assertio has a consensus price target of $2.75, suggesting a potential upside of 257.14%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Assertio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of PRQR or ASRT? 32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 4.0% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, PRQR or ASRT? ProQR Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Does the media favor PRQR or ASRT? In the previous week, ProQR Therapeutics' average media sentiment score of 0.00 equaled Assertio'saverage media sentiment score. Company Overall Sentiment ProQR Therapeutics Neutral Assertio Neutral SummaryAssertio beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.26M$2.43B$5.57B$9.42BDividend YieldN/A1.80%4.05%3.99%P/E Ratio-2.419.1428.1520.08Price / Sales0.59540.89401.6884.07Price / Cash14.73166.9336.1958.45Price / Book0.615.168.625.83Net Income-$21.58M$30.99M$3.24B$258.27M7 Day Performance14.93%3.81%3.55%2.69%1 Month Performance20.84%12.26%11.01%12.91%1 Year Performance-49.34%0.95%35.56%21.81% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio1.6323 of 5 stars$0.77+6.5%$2.75+257.1%-52.5%$69.26M$124.96M-2.4120PRQRProQR Therapeutics2.1633 of 5 stars$2.48+6.9%$8.00+222.6%+15.1%$260.92M$20.46M-7.09180INZYInozyme Pharma2.8834 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750TRDAEntrada Therapeutics2.9145 of 5 stars$6.80+3.8%$25.67+277.5%-62.8%$258.08M$172.22M8.40110ACBAurora Cannabis0.2731 of 5 stars$4.58+2.0%N/A-20.4%$257.44M$246.72M41.641,130IMMPPrima BioMed1.0211 of 5 stars$1.69+2.4%$7.00+314.2%-17.6%$246.81M$5.14M0.002,021Positive NewsUpcoming EarningsNBTXNanobiotix1.9259 of 5 stars$5.15-0.4%$8.00+55.3%+8.9%$242.72M$39.18M0.00100Gap DownFENCAdherex Technologies2.4838 of 5 stars$8.79+0.1%$13.00+47.9%+30.3%$242.60M$47.54M-17.2410TKNOAlpha Teknova2.1974 of 5 stars$4.49-6.7%$12.00+167.3%+103.2%$239.95M$38.25M-9.35240News CoverageAnalyst UpgradeEDITEditas Medicine4.0725 of 5 stars$2.85-1.0%$4.70+64.9%-38.3%$238.57M$32.31M-0.94230Gap UpSCPHscPharmaceuticals4.415 of 5 stars$4.48+2.3%$14.00+212.5%+9.1%$236.50M$36.33M-2.3530Positive News Related Companies and Tools Related Companies ProQR Therapeutics Competitors Inozyme Pharma Competitors Entrada Therapeutics Competitors Aurora Cannabis Competitors Prima BioMed Competitors Nanobiotix Competitors Adherex Technologies Competitors Alpha Teknova Competitors Editas Medicine Competitors scPharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASRT Stock Alerts